A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer-Reference-Cited by-同舟云学术

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Published:2016-03 Issue:3 Volume:69 Page:450-456
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Powles Thomas,Wheater Matthew,Din Omar,Geldart Thomas,Boleti Ekaterini,Stockdale Andrew,Sundar Santhanam,Robinson Angus,Ahmed Imtiaz,Wimalasingham Akhila,Burke Wendy,Sarker Shah-Jalal,Hussain Syed,Ralph Christy

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. RECORD-1 Study Group;Motzer;Lancet,2008

2. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007

3. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N Engl J Med,2012

4. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope;De;Cancer Treat Rev,2013

5. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor;Hoang;Blood,2010

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection and validation of reference genes for RT-qPCR normalization in dormant cancer cells;2024-09-13

2. Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-26

3. Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma;Nature Reviews Urology;2024-05-02

4. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track?;Current Medicinal Chemistry;2024-04-04

5. Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors;BMC Cancer;2023-12-06